Superior immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated)

详细信息	查看全文 | 推荐本文 |

• 作者：Akiko Kikukawa^a ; Yasuyuki Gomi^a ; Masateru Akechi^b ; Toshiyuki Onishi^a ; Sadao Manabe^a ; Junko Namazue^b ; Isao Fuke^a ; Toyokazu Ishikawa^a ; Yoshinobu Okuno^a ; Shigeharu Ueda^b ; ^{akikukawa@mail.biken.or.jp} ; ^{s-ueda@mail.biken.or.jp}
• 关键词：Japanese encephalitis ; Vaccine ; Vero cells ; Potency
• 刊名：Vaccine
• 出版年：2012
• 期刊代码：89_0264410x
• 类别：imm
• 出版时间：16 March, 2012
• 卷：30
• 期：13
• 页码：2329-2335
• 文件大小：361 K

摘要

Japanese encephalitis is an infectious disease caused by the Japanese encephalitis virus, which is widespread throughout Asia. The worldwide incidence is 50,000 cases per year. There is no specific treatment available, but inactivated mouse brain-derived vaccine was used from the 1950s to prevent infection. However, quality control of mouse brain-derived vaccines is difficult, and therefore a new freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated) (JEBIK V; development code: BK-VJE) was developed. In this paper, we report an analysis of neutralizing antibody titers in vaccinated subjects enrolled in clinical study of BK-VJE at various doses, and study of BK-VJE with the mouse brain-derived vaccine as a control. The results show that BK-VJE has superior immunogenicity compared to mouse brain-derived vaccine.